|
Median age (range)
|
67 yr
|
(39–91 yr)
|
|
Gender:
|
|
Male
|
70
|
(73%)
|
|
Female
|
26
|
(27%)
|
|
Primary tumor stage:
|
|
Stage I
|
4
|
(4%)
|
|
Stage II
|
6
|
(6%)
|
|
Stage III
|
19
|
(20%)
|
|
Stage IV
|
60
|
(63%)
|
|
Unknown
|
7
|
(7%)
|
|
Prior definitive therapy:
|
|
Radiation only
|
9
|
(9%)
|
|
Chemo + radiation
|
11
|
(12%)
|
|
Surgery + radiation
|
30
|
(31%)
|
|
Chemo, surgery + radiation
|
46
|
(48%)
|
|
Median prior radiation to head and neck
|
70 Gy
|
(36–139 Gy)
|
|
Median time from prior radiation to first recurrence
|
10 mo
|
(1.4–188 mo)
|
|
Median time from prior radiation to SBRT
|
12 mo
|
(2.4–179 mo)
|
|
Median SBRT dose
|
44 Gy
|
(25–50 Gy)
|
|
Median tumor volume
|
26.3 cc
|
(1–205 cc)
|
|
Use of cetuximab with SBRT
|
41
|
(43%)
|
|
Patients with other distant or untreated tumors
|
40
|
(42%)
|
|
Patients treated as adjuvant to surgery
|
7
|
(7%)
|
|
Sites treated with SBRT:
|
|
Oral Cavity
|
15
|
(16%)
|
|
Nasopharynx
|
7
|
(7%)
|
|
Oropharynx
|
13
|
(14%)
|
|
Hypopharynx
|
7
|
(7%)
|
|
Larynx
|
7
|
(7%)
|
|
Retropharynx
|
5
|
(5%)
|
|
Neck
|
19
|
(20%)
|
|
Base of Skull
|
10
|
(11%)
|
|
Paranasal Sinuses
|
5
|
(5%)
|
|
Other
|
8
|
(8%)
|
